BIO-RAD LABORATORIES, INC. (BIO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net sales | 651,600 | 585,400 | 649,729 | 638,476 |
| Cost of goods sold | 306,300 | 279,400 | 293,826 | 283,357 |
| Gross profit | 345,300 | 306,000 | 355,903 | 355,119 |
| Research and development expense | 60,500 | 73,500 | 90,997 | 58,904 |
| Selling, general and administrative expense | 207,700 | 208,800 | 200,440 | 194,719 |
| Segment profit (loss) | 77,100 | 23,700 | 64,466 | 101,496 |
| Marketable securities, unrealized (gain) loss | 334,400 | 31,800 | 792,888 | -2,895,355 |
| Interest expense | 12,600 | 12,000 | 12,174 | 12,264 |
| Foreign exchange (gains) losses, net | -1,100 | 2,700 | -1,641 | 1,699 |
| Other nonoperating income (expense) | 16,200 | 37,200 | 18,081 | 18,143 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | 414,000 | 83,400 | 861,620 | -2,786,281 |
| (provision) benefit for income taxes | 96,200 | 19,400 | 208,448 | -620,795 |
| Net income attributable to bio-rad | 317,800 | 64,000 | 653,172 | -2,165,486 |
| Net income per share basic attributable to bio-rad | 11.67 | 2.29 | 23.37 | -76.26 |
| Net income per share diluted attributable to bio-rad | 11.67 | 2.29 | 23.34 | -76.26 |
| Weighted average common shares - basic | 27,226,000 | 27,941,000 | 27,949,000 | 28,395,000 |
| Weighted average common shares - diluted | 27,228,000 | 27,955,000 | 27,985,000 | 28,395,000 |